Policy and Medicine

CBI 4th Annual Life Sciences Forum on Speaker Program Management

On February 23-24, 2012, CBI will be hosting its 4th Annual Life Sciences Forum on Speaker Program Management.  The two-day meeting, which includes a distinguished group of speakers, will be hosted at the Double Tree Hotel, located in Philadelphia, PA.

CBI, a subsidiary of Advanstar, is the leading provider of market-driven, unbiased conferences for the pharmaceutical, biotechnology, medical device and healthcare industries. CBI offers specialized information presented in interactive formats by thought leaders and regulators.

Conference

The implications of Healthcare Reform are still changing the way pharmaceutical and medical device companies are managing and monitoring their speaker bureaus.  This forum brings together experts in speaker program management to discuss compliant practices and innovative formats that are increasing the value and ROI of speaker programs within their organizations.

Program Highlights Include:

Practical Guidance on Moving Forward with Tracking and Reporting Speaker Programs

• Ensure Speaker Compliance – How to Educate and Communicate Regulations
• Keep Speaker Programs Fresh and Improve Audience Engagement
• Educate and Train the Sales Force on Speaker Programs
• Understand the Crucial Factors that Drive Physician Attendance at Speaker Programs
• The Digital Age of Speaker Programs – Evaluate Alternative Avenues and Successful Practices for New Mediums of Speaker Programs
• Application and Implementation of ROI for Speaker Programs 

 A brief summary of the agenda is listed below. 

Sunshine Act 

Several of the sessions will focus on the Physician Payment Sunshine Act, which has already made a profound impact on the life sciences industry and merited a tremendous shift in how speaker programs are developed, managed and executed.  Now with the release of partial reporting in 2012, what will this mean for speaker bureau professionals?  As individuals involved with speaker program management, at every level, it is critical to maintain compliant and transparent interactions with HCPs through programs.  

CBI’s 4^th Annual Life Sciences Forum on Speaker Program Management helps industry professionals benchmark with peers and develop proven strategies for addressing key regulatory updates with speaker programs.

• Learn how to track and report speaker programs in 2012
• Understand how to educate speakers on current regulations
• Establish disciplinary procedures for non-conforming speakers
• Review the impact of the Sunshine Act on speaker programs 

Tom Sullivan will be giving the opening address entitled, “Walking with Sunshine on Your Shoulders — Visibility into the Future of Speaker Programs.  If there was ever a shift in the way speaker programs are developed, executed and monitored – it is now.  In an effort to increase federal transparency for the benefit of the patient, pharmaceutical, biotech and medical device companies now have a time-consuming task on their hands.  But tracking and reporting every bit of spend is only the beginning – the public database that will result from such efforts will impact every piece of speaker programs and every person involved.  From the KOLs to the speaker bureau managers, learn what Sunshine has to hold for the future. 

Another session focusing on Sunshine will be the “Practical Guidance on Moving Forward with Tracking and Reporting Speaker Programs,” led by Steven Franchetti, Director, Integrity and Compliance at Novartis Vaccines and Diagnostics, Inc.

His discussion will look at how the Sunshine Act has already made a profound impact on the way speaker programs are developed, managed and executed.  With a significant change in the regulatory environment, comes a significant adjustment period for professionals managing HCP relationships.  During this session, he will examine how large or small companies are implementing compliance strategies to remain compliant with the Sunshine Act and develop new policies to track and report all spend. The session will look at: 

• Accurate tracking and reporting of spend
• State and federal regulations
• The cost of staying compliant
• Use of third party vendors 

In addition, Luanna Saulino, Associate Director, Disclosure Law and Transparency Operations for Bayer HealthCare will give a talk entitled, “Ensure Speaker Compliance — How to Educate and Communicate Regulations.” Her talk will center on the changing regulatory landscape and how this affects influential HCPs that participate in speaker programs.  The Sunshine Act not only affects the companies who administer speaker programs, but also HCPs who speak on behalf of countless brands.  What information do we need to communicate in order to remain compliant?  What kind of questions are HCPs asking and how can we address them?  Learn HCP expectations and reactions in the new regulatory environment to maintain powerful and robust speaker programs.  This session will examine 

• Best practices for compliance education techniques
• Ensure your HCPs understand the regulations
• Consequences of non-complianc
• Learn expected FAQs
• Identify simple answers to tough questions 

In light of the recent proposed Sunshine regulations, CBI’s conference holds a lot of promise for all stakeholders that work and collaborate with industry.  Attendance will provide stakeholders with important insight into the Sunshine regulations, potential risks and liabilities, and the best approaches to achieve compliance with the regulations.

CBI 9th Forum on Educational Grants: Ensure Compliant and Transparent Funding while Improving Outcomes Measurement for Medical Education Programs

 
On September 12th and 13th, 2011, the Center for Business Intelligence (CBI) will be holding its 9th Forum on Educational Grants: “Ensure Compliant and Transparent Funding while Improving Outcomes Measurement for Medical Education Programs.”

The meeting will take place in Philadelphia, PA.

CBI's 9^th Forum on Educational Grants will discuss the challenges surrounding commercial support for medical education programs.  This event, led by continuing medical education (CME) experts from supporter and provider organizations, provides a forum to discuss how to overcome challenges and maintain compliance in the funding of outcomes-driven educational programs. 

Topics in development include:

• Examination of transparency measures and compliant reporting of grant funding
• Grant evaluation processes
• Considerations for grant reconciliation
• Development of a clear, concise CME value proposition

For more information or to register, please contact CBI toll free by phone at 1-800-817-8601 or via e-mail at cbireg@cbinet.com.

A number of well known health care professionals from industry and CME will be participating according to the Agenda and Speaker list.

I will be giving a presentation during a panel entitled, “Healthcare Changes Impacting Educational Grants — Identify Opportunities for CME Providers and Supporters under the Affordable Care Act.”

In this session, we will examine how the Affordable Care Act (ACA) is positioned to affect the CME industry. Many federal programs may not receive full funding and the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) may also face shrinking budgets.  Attendees will examine opportunities for CME providers and supporters under ACA and learn about key initiatives including:

• Accountable Care Organizations
• ACA effects on key constituents including hospitals/group practices and insurance providers
  •  emphasis on quality measures and health IT

• What will REMS CME mean to accredited providers?
  • discussion on REMS and surrounding guidance
  • how long-acting opioid REMS is a testing ground

Other panel members include Matthew Farber, MA, Director, Provider Economics and Public Policy, Association of Community Cancer Centers, and Peter Pitts, President Center for Medicine in the Public Interest.

CBI Med Ed Forum March 21-22 Offers Insight on Improving Outcomes and Quality of Patient Care

 
The Center for Business Intelligence (CBI) will be holding a Medical Education Forum entitled, “Improve Outcomes through Collaboration to Maximize the Quality of Patient Care.”

The forum, which will be held in Philadelphia on March 21-22, 2011, will provide a platform where industry continuing medical education (CME) professionals and CME providers can collaborate with one another to better the design and outcomes of CME programs. Industry and providers can work together to progress the way they teach physicians, demonstrate outcomes, and advocate in the community for CME activities. The program will offer participants the opportunity to:

• Collaborate with one another to help design effective learning programs for healthcare providers
• Address reporting, presentation, assessment and financial feasibility of outcomes
• Improve advocacy efforts internally and externally to combat the negative perception of CME in the community
• Choose between two breakout sessions addressing the needs of industry grantors and education providers
• Hear twelve perspectives from leading pharmaceutical and medical device companies
• Interact with and learn from speakers at ten different education provider companies
• Enjoy shared exhibit space and networking breaks with CBI’s Premier Forum on Training, Learning and Development

Agenda

During the first day of the forum, I will be giving the Opening Address, reflecting on the “State of Medical Education: CME and Healthcare Reform.” My opening remarks will touch on how the new Congress will handle issues like CME, both commercial and non-commercial. I will also discuss the changing landscape on Capitol Hill, up-to-date rules and regulations from the ACA and updates on:

• How the Sunshine Act affects the way medical education programs are managed
• The potential of how to optimize REMS by demonstrating support of medical education
• What role comparative effectiveness research has in developing CME content
• Where follow-on biologics will step in to increase the needed amount of CME

Another session during the forum that holds promise is the role of medical schools and universities in providing CME. To address this issue and to discuss pharma’s role in academic CME and understand how to avoid undue regulatory scrutiny, Victor Marrow, Ph.D., Executive Director for the Office of Funded Programs, CME at John Hopkins School of Medicine will explore:

• The meaning of the “Educational Grant”
• ACCME and the notion of “Safe Harbor”
• Conflict of interest
• Existing opportunities to limit pharma’s legal liability

Alicia Reese, Manager of Scientific Affairs at Endo Pharmaceuticals, will discuss the increasingly important need to understand the evolving role of nurse practitioners (NPs) and physician assistants (PAs). She will explain why this group should be integrated into educational strategies and allotted for in CME budgets, and will focus on how CME providers can effectively assess and meet their educational needs in primary care.

Another presentation on the first day will look at “Outcomes-Based Design for Physician Training –The Key to Behavior Change in a Changing World.” This session will highlight emerging learner demographics and shows how adult learning principles and innovative technologies can support behavior change. Additionally, this session covers how to link outcomes to learning objectives and educational strategy in order to maximize behavior change. Participants apply their new knowledge via an interactive teaching case throughout the session. 

There will also be a poster session that will showcases examples within the CME world that demonstrate either an outcome that enhanced the quality of patient care or an innovative strategy for effective advocacy. Other sessions that will offer valuable information for CME providers and stakeholders include:

• Global CME Environment — Determine Opportunities Abroad
• CME 2.0 — The Role of Emerging Technologies to Enhance the Learning Experience
• Overcome Challenges of Performance Improvement Programs— Interactive Breakout Discussions —
• Measurement and Metrics for Change in HCP Behavior
• The Role of the Patient in Medical Education
• Best Practices, the Value Proposition and Moving Forward

There will also be two breakout sessions. The first will be for Industry Grantors and will discuss “Strategic Grant Funding Decisions.” This industry-focused discussion will highlight key considerations in funding decisions and how to ensure quality from providers. It will also touch on systems to rank the most important factors in grant evaluation — needs assessment, educational design, cost and levels of outcomes or performance improvements promised. The session will identify:

• Best practices in assessing grant submissions
• Key elements of a grant review
• Insight into the supporting material provided with a grant submission
  • provider outcome levels 
  • educational design
  • historical success of program

Industry participants will also have the opportunity to attend a session regarding the “Best Practices in Communication with CME Providers.” This session will explain the risks and benefits of provider-supporter interactions and discuss various initiatives regarding provider-supporter dialogue.

The breakout session for CME providers will discuss the “Financial Feasibility of Outcomes.” This session will explore the staffing and resources needed to effectively compile, analyze and report outcomes data, understand the budget implications of the various outcomes assessment methodologies including PI-CME. It will also allow participants to: 

• Formulate ideas on how to operationalize the higher levels of outcomes within your particular organization
• Understand how this process will help providers build stronger grant requests

Another session for CME providers will offer participants guidance and details on ways to effectively present educational outcomes to grantors to help them demonstrate importance of CME funding. It will also explore practical ways CME providers can improve outcome processes and observe concrete examples that can be implemented tomorrow.

Resources

CBI Conference Overview

Registration

Agenda

Speakers

FDA Boot Camp -- Hooah

 
As the regulatory landscape for pharmaceutical and medical device companies continues to rapidly change, and as key provisions of health care reform and begin their implementation at federal health agencies, there is a tremendous need to educate stakeholders in the health care industry about these new developments.

Additionally, recent court cases and high-profile trials concerning FDA-regulated products have made it clear that it is essential for attorneys who do not have regulatory practices — but who do deal with FDA-regulated products — to have a familiarity with these concepts.

To address these recent developments, the American Conference Institute will be holding a conference entitled, “FDA Bootcamp,” to assist health care industry professionals in navigating through the complex regulatory framework of federal agencies.

The conference will be held on March 16 – 17, 2011, in Flatotel, New York, and will offer basic training for products liability and patent lawyers. The conference offers continuing legal education credits as well, and will include a distinguished faculty of top FDA regulatory experts — a “Who’s Who of the FDA Bar”— that will share their knowledge and give critical insights on:

• The organization, jurisdiction, functions, and operations of the FDA
• The essentials of the approval process for drugs, biologics, and devices, including:
• NDAs - OTC Approval
• INDs - 510(k) submissions
• BLAs - PMA process
• Clinical trials for drugs and biologics and the clearance process for devices
• The classification of devices and the concept of “risk-based” classification
• The role of the Hatch-Waxman Act in the patenting of drugs and biologics
• Labeling in the drug and biologics approval process
• cGMPs and other manufacturing concerns relative to products liability
• Proactive adverse events monitoring and signal detection
• Recalls, product withdrawals, and FDA oversight authority

Presentations from faculty members such as Arnie Friede, former FDA Associate Chief Counsel, and former Senior Corporate Counsel for Pfizer, Inc., are focused on a number of objectives to help participants:

• Master the basics of the application and approval processes for drugs, biologics, and devices
• Comprehend the structure of the FDA and the roles of the three major agency centers: CDER, CBER, and CDHR
• Develop a practical working knowledge of clinical trials for drugs and biologics and the clearance process for devices
• Learn how devices are classified, monitored, and regulated
• Appreciate the complexities of pharmaceutical IP and the regulatory balance between brand name and generic products
• Recognize the pivotal role of labeling in the drug and biologics approval process
• See the importance of cGMPs to the post-approval regulatory process
• Navigate the protocols of adverse events monitoring, signal detection, product withdrawals, and recalls

ACI’s FDA Boot Camp was designed to give products or patent litigators, as well as patent prosecutors and life sciences investment and securities experts, a strong working knowledge of core FDA competencies. This conference offers important insight into what happens during the pre-approval, approval, or post-approval periods, which have a significant impact on products liability and patent litigation concerning FDA-regulated products.  The topics covered during the two-day conference include:

• The Basics: Understanding and Working with the FDA — Jurisdiction, Functions, Organization, and Operations
• The Nature of the Approval Process
• Understanding the Clinical Trial Process for Drugs and Biologics
• Patent and IP Overview: Hatch-Waxman, Trade Dress, and More
• Drugs and Biologics: Labeling
• cGMPs: Drugs and Biologics (current Good Manufacturing Practices)
• Follow-On (Comparable or Biosimilar) Biologics
• Bioequivalence: What Patent Lawyers Need to Know
• Challenges, Opportunities, and Current Controversies with the (Non-Patent) Marketing Exclusivities
• Advertising and Promotion
• Off-Label Promotion and Criminal Enforcement
• Preemption Fundamentals
• Adverse Events Monitoring, Pharmacovigilance and Risk Management
• Medical Devices: Classification and the Essentials of the Device Premarket Review Process
• Post-Market Requirements and Concerns for Medical Devices
• Recall Guidance for Drugs, Biologics, and Medical Devices: What You Need To Know

For more information about FDA Bootcamp, faculty, presentations or to register, click here.

21st Annual Conference of the National Task Force on CME Provider/Industry Collaboration

 
The 21st Annual Conference of the National Task Force on CME Provider/Industry Collaboration will be held October 13–15 in Baltimore. The theme of this year is “Moving forward in an age of uncertainty; creating innovative, practical educational solutions.”

Featured sessions at this year’s conference include:

Keynote address, “Principled partnerships: Practical or pipe dream?” Darrell G. Kirch, MD, Association of American Medical Colleges

“Working together within the guidelines: Interactive case studies”

“IOM Report: Redesigning CME—what does this mean for you?”

“Providing meaningful outcomes in a collaborative approach: A panel discussion with the stakeholders”

“Everything you always wanted to ask grant officers but didn’t have the guts or chance to ask”

There will be two major announcements at the meeting: 

On Thursday John Kamp, JD Executive Director of the Coalition for Healthcare Communications will present his vision for CME going forward. 

Stephen Lewis of the Global Education Group will be releasing a white paper on the CME environment on Wednesday.  

Thomas Sullivan is participating in two panel presentations on Transparency and the Physician Payment Sunshine Act: How to Comply with Evolving Federal and State Laws this Friday October 15th. 

Visit the conference website for additional information and registration.

ACC 2010 Features Debate on Industry Support of Education

On Tuesday March 16^th at 8:00am, there will be a debate at the American College of Cardiology Meeting in Altanta Georgia on Industry support, academic actitivity and physician education:  are the potential influences collaborative or confounding.

The debate features Robert Harrington, MD, Director of the Duke Clinical Research Institute vs. Steven Nissen, MD, Chief of Cardiology at the Cleveland Clinic.

Both have been strong advocates for their positions.  This past summer Dr. Nissen testified in the Senate Aging Committee hearing on CME. This promises to be a lively event.

Session Title:	Industry Support, Academic Activity, and Physician Education: Are the Potential Influences Collaborative or Confounding?
Session Type:	ACC Symposium
Session Start/End Time:	Tuesday, Mar 16, 2010, 8:00 AM - 9:30 AM
Location:	Georgia World Congress Center, Room B212
CME/CE Hours:	1.5
Presentations: 0659-1: Co-Chair Tuesday, Mar 16, 2010, 8:00 AM - 9:30 AM Raymond J. Gibbons Rochester, MN 0659-2: Co-Chair Tuesday, Mar 16, 2010, 8:00 AM - 9:30 AM W. Douglas Weaver Detroit, MI 0659-3: Industry's Potential Influence Does Not Affect the Academic Process nor Confound the Education of Physicians Tuesday, Mar 16, 2010, 8:00 AM - 8:30 AM Robert A. Harrington Durham, NC 0659-4: Industry's Potential Influence Does Affect the Academic Process and Confound the Education of Physicians Tuesday, Mar 16, 2010, 8:30 AM - 9:00 AM Steven E. Nissen Cleveland, OH 0659-5: Protagonist, Rebuttal Tuesday, Mar 16, 2010, 9:00 AM - 9:15 AM 0659-6: Antagonist, Rebuttal Tuesday, Mar 16, 2010, 9:15 AM - 9:30 AM

Conferences: 4th Annual Pharmaceutical Funded CME: Envisioning the New Paradigm

 

As we read the headlines about the Senate Hearings and Corporate Integrity Agreement it is clear that Commercially Supported CME is at a crossroads. 

 

Now is the time for industry professionals to join together to explore and discuss the current state of Medical Education.  One opportunity is to learn and share with the faculty of this crucial event on September 24^th and 25^th in Philadelphia.  Many of the major issues impacting the work you do will be on the agenda, including: 

 

 

Pre Conference Workshop:

 

What do people do in the sessions you fund: what, exactly, does it mean “to teach” and “to learn?”

 

Hank Slotnick PhD, Professor Emeritus, UNIVERSITY OF NORTH DAKOTA

 

Judith Ribble, PhD, CCMEP,

Executive Director, National Commission for Certification of CME Professionals, Inc., NC-CME

 

Public Disclosure & Reporting Of Financial Support - Next Steps

 

 Beth Brillinger, Sr. Manager, Medical Education Grants, Astra Zeneca

 

 Karen Small, Sr. Manager, Medical Education Grants, Astra Zeneca

 

Catalyst For Change: Finding Growth Opportunities In The New Environment

 

Theresa M. Vera, PhD, Manager, Medical Education, Medical & Scientific Affairs, Takeda Pharmaceuticals North America Inc.

 

Group Discussion

 

The Future Of Commercially Supported CME

 

Led by Brian McGowan, Senior Director, IME, WYETH

 

Cephalon Group Presentation:

Grant Request Review: The Good, the Bad and the Ugly!

 

Cephalon Presenters:

 

Karen Roy, MSc, Director Medical Education

 

Sue McGuinness, PhD, Manager, Medical Education

Bhaval Shah Bell, PhD, Associate Director, Medical Education

 

Moderator:

Barbara A Fuchs, CCMEP, CPHQ, Consultant, EPIQ Services, LLC

 

Understanding The Pharma Cme Planning Process

 

Laura Muttini, RPh, MBA, CCMEP, Associate Director, Pharmaceutical Products Division, Grant Management Department, Abbott

 

Grant Requests: Through The Lenses Of The Corporate Sponsor

 

Kimberly Boothe, PharmD, MHA, BCPS, Deputy Director, Medical Education & Investigator Sponsored Studies, Bayer Healthcare

 

 

PhRMA Code - Interpretations and Implications

 

Barbara R. Giddings, RN, MHA, CHC, Commercial Compliance, Biogen Idec

 

Metrics and Rate Card Benchmarking For Budgets

 

Germaine Aprill, PharmD, Director, Independent Medical Education, ASTELLAS PHARMA US, INC.

 

Current Outcome Levels: Are Commercial Supporters Getting What They Need?

 

Jason M. Singer, PharmD, CCMEP, Senior Grant Associate, Lilly Grant Office, Lilly USA

 

Making A Case For The Value Of CME: Time To Move Beyond The Reactive To The Pro-Active

 

Michael J. Paradiso, Director, Novartis Office of Grants & Education, Medical Information & Communications, NOVARTIS

 

For more information or to register online at: www.exlpharma.com/grants

Conferences: 4th Annual Forum on Educational Grants for the Bio/Pharmaceutical Industry

On September 14^th and 15^th leaders of the CME Community including Thomas Sullivan, of Policy and Medicine will be meeting on a variety of issues related to CME at the 4^th Annual Forum on Educational Grants for the Bio/Pharmaceutical Industry in Philadelphia.

Tom will be presenting two topics:

On Monday December 14th

Discuss Conflict of Interests, IOM, CEJA and New ACCME Regulations
Recent reports and criticism surround the debate on how commercial support for CME affects conflict of interest and bias. Mounting criticism has impacted accredited CME causing fundamental changes within institutions, societies, funders and healthcare organizations and the need to address conflict of interest and control bias. The CME community is seeing a shift towards greater transparency. During this session, hear updates on recent reports (IOM, CEJA, etc.) and new ACCME regulations dealing with these issues. How will they impact the way industry continues to review and analyze medical education programs for grants?

• Examine recent reports and regulations
• Discuss the impact on authors and program content
• Review how institutions have shifted their policies
• Look at how providers are adapting to these changes

With Brad Bednarz the Chief Strategy Officer at Visible Productions

On Tuesday December 15^th

Healthcare Reform and Political Context of Medical Education
What impact will the stimulus package and healthcare reform have on medical education? With new congressional initiatives, MedEd focus has concentrated on issues like comparative effectiveness, strategic planning and understanding potential outcomes. Where will CME fall within congressional initiatives? Participate in an open discussion on the healthcare reform and identify the impact on medical education. During the final Q&A portion of this session, audience members identify practical solutions for funding educational programs in alignment with the healthcare reform and future congressional initiatives.

• Review the passage of the stimulus package and the healthcare reform
• Discuss how comparative effectiveness plays a role in medical education
• Analyze effective maintenance of certification CME and medical board requirements

Other Speakers include:

• Beth Brillinger, CCMEP, Senior Manager, Medical Education Grants Office (MEGO), AstraZeneca LP
• Derek T. Dietze, MA, CCMEP, President, Improve CME, LLC.
• Marc Eigner, Partner, Polaris Solutions
• Sue Garnett, RPh, MBA, Executive Director, Scientific Education, Celgene 
• Patty Jassak, Senior Director, Medical Education, sanofi-aventis
• Elizabeth Jobes, JD, Chief Compliance Officer, Adolor
• Bryan King, Director, Medical Education, GlaxoSmithKline
• Sharyn S. Lee, RN, MS, DHL, CCMEP, President and CEO, MEBN 
• Stephen M. Lewis, MA, CCMEP, President, Global Education Group
• Brian S. McGowan, Ph.D., CCMEP, Senior Director, Independent Medical Education, Wyeth Pharmaceuticals 
• Mindi McKenna, Ph.D., MBA, Director, Division of Continuing Medical Education, American Academy of Family Physicians
• Bob Meinzer, Senior Director, National CME, NJAFP 
• William Mencia, M.D., Vice President, Education & Medical Affairs, Med-IQ
• Lisa Miller, Pharm.D., MBA, Executive Director, Healthcare Education and Liaison Programs, Purdue Pharma L.P. 
• Karen M. Overstreet, EdD, RPh, FACME, CCMEP, Executive Director, Lippincott CME Institute, Wolters Kluwer Health Medical Research; President, National Commission for Certification of CME Professionals
• Sam Patel, RPh, MBA, Director National Education & Strategy (NES), MEDA Pharmaceuticals
• Karen Roy, Director, Medical Education, Cephalon Inc.
• Edward Wang, Ph.D., Medical Director, Scientific Officer, sanofi-aventis

To register for the conference:  https://www.cbireg.com/webreg/RegGate.wbr?PC09169

CBI West Coast Forum on Educational Grants

Another Educational Opportunity includes the 3rd Annual West Coast Forum on Educational Grants for the Pharmaceutical, Biotech and Medical Device Industry.

Topics include:

• Improved transparency
• MedEd needs assessments
• What’s happening on the Hill
• The impact of PhRMA 2009
• How to ensure effective collaboration with providers
• NC-CME certification process
• Adult learning
• Independent medical education departments
• Establish SOPs
• Cost benefit analysis of online/offline grant systems
• Outcomes data

This event is focused on the internal workings of grants systems at manufacturers, it is a good event especially if you live or work on the west coast to understand how commercial support for CME works in today’s environment.  And as a bonus you get hear Thomas Sullivan, Author of Policy and Medicine present on the latest issues.

Dates:  Tuesday May 12^th – Wednesday May 13^th

Location:  San Diego Hilton

For More Information

To register

PACME Spring Summit

The Pharmaceutical Alliance for Continuing Medical Education (PACME) is hosting their Spring Summit on May 7-8^th at the Sofitel Hotel, in Philadelphia.

 

Topics include:

• Compliance Continuous Improvement Working Session to seek solutions to some of our compliance issues
  •    Representatives from accrediting organizations will serve as resources, comment on recommendations and offer insights for consideration.
• Integration of ACCME Criteria in Grant Applications: Moving from Theory into Action
• Patient-Centered Medical Home
• Political & Legislative Update
• Demonstrating the Value Proposition for Support of CME in Your Institution
• The Future of Medical Education: Beyond CME

For More Information:  PACME Spring Summit 09